Cumberland’s $100 Million Deal Sets Stage for Shift to Development-Stage Biopharma
Key Facts
Cumberland Pharmaceuticals completed a deal with Apotex Health during the second quarter of 2026 to sell its portfolio of approved U.S. branded products and the associated commercial operations for $100 million in cash at closing, according to a company statement. The company added that the agreement included $11 million to fund inventory and transition services. The sale ends the commercial activity represented by the portfolio and opens a phase in which Cumberland will focus on drug development. The company said its post-deal direction is to operate as a development-stage biopharmaceutical company. It said it will focus on differentiated medicines for rare diseases and other areas with significant unmet medical needs.
Continuing operations posted revenue of $166,458 in the second quarter of 2026, compared with $380,797 in the same period of 2025, according to company figures. The loss from continuing operations was $3.1 million for the quarter, while the net loss reached $4.1 million after discontinued operations were included. The company attributed the loss from continuing operations to ongoing investment in research and development, along with remaining general and administrative expenses. The revenue figures reflect the scope of continuing operations after the sale of the commercial portfolio, while the net loss includes the impact of discontinued operations. These figures did not describe third-quarter results, which were scheduled to be announced in November.
Cumberland said in August that the deal had been completed during the second quarter, explaining that Apotex acquired the company’s approved U.S. brands and commercial operations. In addition to the cash consideration at closing, additional funding was allocated for inventory and transition services associated with transferring the business. On July 31, Cumberland paid a special cash dividend of $1.50 per share to shareholders of record on July 23. The dividend followed completion of the deal, returning part of the cash to shareholders. These steps provide the financial context for the company’s announced shift from marketing an established portfolio to funding development activities.
On its development pipeline, the company announced on October 26 its plan to submit a New Drug Application to the U.S. Food and Drug Administration for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy. The announcement was based on the 12-month Phase 2 FIGHT DMD trial. Cumberland said the high dose produced an absolute improvement of 5.4% in left ventricular ejection fraction compared with a composite control group, with reported statistical significance at p=0.002. It also said the agency granted the company’s application rolling review, allowing completed sections to be submitted for review before the full application is filed. This means the filing process can begin with the sections that are ready while the rest of the application is completed.
The ifetroban path, however, includes regulatory issues that were not resolved in the plan announcement. The company said the FDA proposed a Phase 3 trial after an end-of-Phase 2 meeting and a follow-up meeting. The agency raised issues related to the suitability of left ventricular ejection fraction as a measure, questions about the comparator, and development of the statistical analysis plan. These comments follow the Phase 2 result on which the company based its plan to submit the application. The design of the subsequent study, along with comparator and analysis issues, therefore remains part of the regulatory discussion around the treatment’s development.
In its systemic sclerosis program, Cumberland announced preliminary results on October 23 from the ASSIST-SSc trial, describing it as an exploratory Phase 2a study to assess safety. It said the trial’s size and design do not allow conclusions about treatment efficacy. The company’s disclosures about the study therefore remain focused on safety, while assessing the treatment’s potential requires additional information from participant follow-up. The company had pointed to biomarker monitoring and cardiac imaging among the factors that would guide its development decision. The program is part of the company’s new focus on developing treatments for rare diseases and unmet medical needs.
Cumberland said on November 3 that it would provide a company update and third-quarter results after the market close on November 10, 2026. It also announced a call to discuss the results and update at 4:30 p.m. Eastern time that day. According to the market data provided, the company’s shares, traded under the ticker CPIX, closed at $5.37 on November 9. That price reflects the session on the day before the announced results date. Details of the third-quarter financial results were not available in the information verified here.